A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500400-22-00

Acronym

MK-3475-204

Enrollment

114

Registered

2022-11-11

Start date

2016-06-23

Completion date

2025-12-10

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin lymphoma

Brief summary

Progression-free Survival (PFS), Overall Survival (OS)

Detailed description

Objective Response Rate (ORR)

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free Survival (PFS), Overall Survival (OS)	—

Secondary

Measure	Time frame
Objective Response Rate (ORR)	—

Countries

Czechia, France, Germany, Italy, Poland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026